Royalty Pharma (RPRX) Assets Average (2020 - 2026)

Royalty Pharma (RPRX) has 7 years of Assets Average data on file, last reported at $19.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 10.06% year-over-year to $19.7 billion; the trailing twelve-month figure through Mar 2026 stood at $19.7 billion (up 10.06% YoY), and the FY2025 full-year result was $18.9 billion, up 9.36% from the prior year.
• Assets Average advanced to $19.7 billion in Q1 2026, from $19.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $19.7 billion in Q1 2026 to a low of $16.1 billion in Q4 2023.
• A 5-year average of $17.6 billion and a median of $17.6 billion in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average decreased 6.88% in 2023 and grew 12.49% in 2024, its largest moves.
• Tracing RPRX's Assets Average over 5 years: stood at $17.2 billion in 2022, then fell by 6.52% to $16.1 billion in 2023, then climbed by 12.49% to $18.1 billion in 2024, then rose by 7.45% to $19.5 billion in 2025, then advanced by 1.2% to $19.7 billion in 2026.
• Business Quant data shows RPRX's Assets Average at $19.7 billion in Q1 2026, $19.5 billion in Q4 2025, and $18.8 billion in Q3 2025.